(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
The Best Traditional Music Arrangers in History- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Well known SUVs With Low Energy Utilization In 2024 vote
- The best movies to watch this holiday season: Stream 'A Christmas Story Christmas,' revisit 'The Night Before' and discover 'The Baltimorons'
- Find Your Ideal Tea: Six Particular Assortments
- 5 Movies That Leaving an Imprint with Inventive Innovation
- Toyota Motor Europe to roll out smart EV charging through new partnerships
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- A Republican elected governor in California? It's not as far-fetched as it sounds.
